|
Patent landscape, scope, and claims: |
United States Patent 5,635,517 (TNFα reduction): Scope, Claim Construction, and US Landscape
US Patent 5,635,517 is directed to methods for reducing undesirable levels of TNFα in a mammal and to a set of specific “aminoisoindoline” diketone/dioxo compounds used for that purpose. Claim scope is centered on (i) TNFα reduction as the intended pharmacologic effect and (ii) a tight structural formula definition for the active compound class.
What does US 5,635,517 claim, at a structural level?
What is the core claim structure in claim 1?
Claim 1 recites administering an “effective amount” of a compound of a defined formula in which:
- One of X and Y is C═O (a carbonyl)
- The other of X and Y is either:
- C═O (second carbonyl), or
- CH2 (a methylene substituent)
This produces two structural subclasses under the same general formula:
- Monocarbonyl vs methylene subclass (X and Y split as C═O / CH2)
- Dicarbonyl subclass (X and Y are both C═O)
How do dependent claims narrow X and Y?
- Claim 2: X is C═O and Y is CH2
- Claim 7: each of X and Y is C═O
Together, claims 2 and 7 allocate the invention into two mutually exclusive chemical patterns for the substituents at the positions defined as X and Y.
What are the exact compounds covered?
Which specific examples are explicitly claimed in dependent claims 3–6 (X = C═O, Y = CH2)?
These are the four enumerated compounds tied to claim 2:
- Claim 3: 1-oxo-2-(2,6-dioxopiperidin-3-yl)-5-aminoisoindoline
- Claim 4: 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
- Claim 5: 1-oxo-2-(2,6-dioxopiperidin-3-yl)-6-aminoisoindoline
- Claim 6: 1-oxo-2-(2,6-dioxopiperidin-3-yl)-7-aminoisoindoline
All four share:
- the 2,6-dioxopiperidin-3-yl appendage
- an isoindoline core with a specified “amino” position (4, 5, 6, or 7)
- a “1-oxo” feature consistent with the X = C═O / Y = CH2 pattern
Which specific examples are explicitly claimed in dependent claims 8–9 (X = C═O, Y = C═O)?
Claims 7 narrows to the dicarbonyl pattern. Dependent claims then specify two embodiments:
- Claim 8: 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
- Claim 9: 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-5-aminoisoindoline
These share:
- the same piperidinyl appendage (2,6-dioxopiperidin-3-yl)
- an isoindoline core with two carbonyls (“1,3-dioxo”)
What is the product claim scope?
How does claim 10 expand from method to composition?
Claim 10 is a compound selection claim. It claims a compound from a list consisting of:
- 1-oxo-2-(2,6-dioxopiperidin-3-yl)-5-aminoisoindoline
- 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
- 1-oxo-2-(2,6-dioxopiperidin-3-yl)-6-aminoisoindoline
- 1-oxo-2-(2,6-dioxopiperidin-3-yl)-7-aminoisoindoline
Notably:
- Claim 10 does not include the “1,3-dioxo” dicarbonyl embodiments listed in claims 8 and 9.
- Claim 10 is therefore narrower than the method claims that include both X/Y patterns (through claim 1 and dependent 7/8/9).
How broad is “method of reducing undesirable levels of TNFα”?
What is the functional boundary?
Claim 1 frames the method as:
- “The method of reducing undesirable levels of TNFα in a mammal”
- requiring “administering thereto an effective amount” of the defined compound
Key scope effects:
- The claims cover any mammal (no disease limitation is stated in the claim text you provided).
- The method is defined by pharmacodynamic endpoint (TNFα reduction), not by a specific indication (e.g., RA, IBD). That tends to expand coverage across multiple TNFα-driven inflammatory states.
What does the absence of disease limitation do to scope?
When a claim is written as a general pharmacologic method tied to a biomarker effect (TNFα reduction) without disease restriction, it typically reaches:
- multiple therapeutic contexts where TNFα is implicated
- off-label use scenarios where the same endpoint is achieved
This makes the method claim broad in concept even if the chemical formula remains narrow.
Claim-by-claim scope map
Claims and their practical reach
| Claim |
Claim type |
Chemical limitation |
Biological endpoint |
Covered entities |
| 1 |
Method |
X/Y pattern is (C═O + (C═O or CH2)) |
Reduce undesirable TNFα levels in a mammal |
Methods using any compound matching the formula with either carbonyl/methylene or carbonyl/carbonyl pattern |
| 2 |
Method (depends 1) |
X = C═O; Y = CH2 |
Same |
The “1-oxo” type embodiments (consistent with claims 3–6) |
| 3 |
Method (depends 2) |
Specific amino position = 5 |
Same |
1-oxo-2-(2,6-dioxopiperidin-3-yl)-5-aminoisoindoline |
| 4 |
Method (depends 2) |
Specific amino position = 4 |
Same |
1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline |
| 5 |
Method (depends 2) |
Specific amino position = 6 |
Same |
1-oxo-2-(2,6-dioxopiperidin-3-yl)-6-aminoisoindoline |
| 6 |
Method (depends 2) |
Specific amino position = 7 |
Same |
1-oxo-2-(2,6-dioxopiperidin-3-yl)-7-aminoisoindoline |
| 7 |
Method (depends 1) |
X = C═O; Y = C═O |
Same |
The “1,3-dioxo” pattern embodiments (consistent with claims 8–9) |
| 8 |
Method (depends 7) |
Specific amino position = 4 |
Same |
1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline |
| 9 |
Method (depends 7) |
Specific amino position = 5 |
Same |
1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-5-aminoisoindoline |
| 10 |
Compound |
One of four listed 1-oxo embodiments (no 1,3-dioxo) |
Not a method endpoint; composition claim |
Composition/product coverage on four members of the broader method set |
Patent landscape implications in the US (based on claim structure only)
What competitors would need to avoid to stay outside literal scope?
Because the claims pin down:
- a specific isoindoline scaffold,
- a 2,6-dioxopiperidin-3-yl substitution,
- and a constrained X/Y carbonyl pattern,
competitors attempting to avoid literal infringement typically must change at least one of the following essential elements:
- the core scaffold identity (isoindoline framework as claimed),
- the piperidinyl substitution pattern (2,6-dioxopiperidin-3-yl),
- the carbonyl substitution state at X and Y positions (C═O/CH2 vs C═O/C═O),
- or the amino substitution position (claims enumerate 4, 5, 6, 7 for the 1-oxo series).
How risk concentrates around “design-around” chemistry
Design-around strategies usually fail when they retain the same pharmacophore:
- same core scaffold
- same piperidinyl appendage
- same TNFα-reduction mechanism via the same binding/biochemical pathway
Given the endpoint-based drafting of the method claims, a competitor cannot “escape” by changing indication if they still reduce TNFα and still use a compound matching the structural formula.
How to interpret the asymmetry between method and composition
Claim 10 covers only four “1-oxo” members (claims 3–6). The “1,3-dioxo” members (claims 8–9) are not covered by the explicit composition selection claim, even though they are included in the method via claim 1 and claim 7.
Practical implication:
- a product that is a “1,3-dioxo” member could still infringe the method if marketed or used in a way that administers an effective amount to reduce TNFα, but it may not be covered by claim 10 as written (depending on additional independent/other claims not provided).
Key Takeaways
- Chemical scope is constrained: claim 1 requires a specific formula framework with X/Y carbonyl state restricted to either (C═O + CH2) or (C═O + C═O).
- Method scope is broad on use: claim 1 covers TNFα reduction in any mammal without an explicit disease limitation in the provided claim text.
- Product coverage is narrower than method coverage: claim 10 is limited to four 1-oxo compounds and does not expressly include the 1,3-dioxo members.
- Design-around targets are clear: literal non-infringement efforts must alter at least one essential claimed structural element, or else risk method claim exposure if TNFα reduction occurs.
- The landscape risk clusters around the isoindoline + 2,6-dioxopiperidin-3-yl pharmacophore and the X/Y carbonyl state.
FAQs
-
Does claim 1 cover both X/Y patterns?
Yes. Claim 1 requires one of X/Y to be C═O, and the other to be C═O or CH2, covering both subclasses.
-
Which TNFα-reducing compounds are explicitly listed for composition protection in claim 10?
Four “1-oxo” compounds with aminoisoindoline substitutions at 4, 5, 6, and 7.
-
Are the “1,3-dioxo” compounds covered by claim 10?
No. “1,3-dioxo” embodiments appear in claims 8 and 9 as method dependents, not in the composition list of claim 10.
-
Is the method limited to a specific disease in the provided claim text?
No. The method is framed as reducing undesirable TNFα levels in a mammal, with no disease limitation stated in the claim text shown.
-
What is the highest-risk attribute for competitors trying to design around?
Maintaining the same claimed chemical core (isoindoline plus 2,6-dioxopiperidin-3-yl) while still achieving TNFα reduction, because the endpoint and the scaffold both align to the asserted method language.
References
[1] United States Patent 5,635,517 (claims as provided by user).
More… ↓
⤷ Start Trial
|
